Aliskiren vs enalapril for C3 kidney inflammation
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether aliskiren works better or as well as enalapril to treat C3 glomerulopathy/dense deposit disease confirmed by a kidney biopsy. It may help by improving kidney outcomes in people with this specific kidney condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a child age 6 or older, or an adult
- Your C3 glomerulopathy or dense deposit disease was confirmed by a kidney biopsy within the last 2 years
- At the start, you either are not on kidney-targeting medicines or you are taking one of these: aliskiren, ACE inhibitors, angiotensin receptor blockers, or immune medicines like mycophenolate or steroids
- Your kidney function is high enough: not too low by the trial’s measured clearance level (varies for children vs adults)
- You can safely take the medicines—no known allergy to aliskiren or enalapril/ACE inhibitors
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called NM8074 for adults with C3 glomerulopathy, a kidney disease. The medicine may help reduce kidney damage. Participants will receive the study drug and be monitored for safety and effectiveness.
This study tests an experimental drug called OMS906 for people with C3G or ICGN (immune-related kidney diseases). It aims to see if the drug is safe and can reduce kidney damage. You may qualify if you have a confirmed diagnosis, high protein in your urine, and stable kidney function.
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
This study follows people in Russia with C3 glomerulopathy or IC-MPGN to understand how these kidney diseases progress over time. It does not test a new treatment, but gathers information from medical records and check-ups to learn more about the conditions.
This study tests an investigational drug called ALN-ANG3 to see if it can help people with diabetic kidney disease. The drug may reduce kidney damage and slow down the loss of kidney function. If you join, you will get the study drug or a placebo (a dummy shot) and be followed by a study doctor.
This trial studies whether iptacopan can improve outcomes and safety for people with C3 glomerulopathy, a kidney disease caused by overactive parts of the immune system. Participants must already be on standard kidney-protecting medicines and meet specific kidney function and urine protein criteria.
Hear when a new C3 Glomerulopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.